β受体阻滞剂短期血流动力学效应对失代偿期肝硬化生存的影响
失代偿患者门压下降更少而心输出量下降更大,β受体阻滞剂下心输出量独立预测死亡。
要点
- 失代偿期肝硬化患者使用β受体阻滞剂后门压下降幅度小于代偿期患者。
- 失代偿患者心输出量下降更显著,且心输出量独立预测死亡。
- 失代偿患者心输出量<5 L/min者死亡风险更高。
核心结论
- 失代偿期肝硬化患者对β受体阻滞剂的全身血流动力学反应更大而门压下降更小,短期心输出量变化可能不利影响生存。
研究设计与样本
- 在开始β受体阻滞剂前及治疗1至3个月后测量全身与肝脏血流动力学。
主要发现
- 基线时失代偿患者门压更高、心输出量更高且动脉压更低。
- 使用β受体阻滞剂后失代偿患者门压下降10±18% vs 代偿患者15±12%(p<0.05)。
- 失代偿患者心率下降更显著(p<0.001),心输出量下降17±15% vs 10±21%(p<0.01)。
- 失代偿患者中死亡者心输出量下降21±14% vs 存活者15±16%(p<0.05)。
- 竞争风险回归显示β受体阻滞剂下心输出量独立预测死亡,C-index 0.74(95%CI 0.66-0.83)。
临床怎么用
- 对失代偿期肝硬化伴高危静脉曲张患者使用β受体阻滞剂时,需关注心输出量下降及生存影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Whether the effect of β-blockers on arterial pressure and/or cardiac function may offset the benefit of reducing portal pressure in advanced cirrhosis is controversial. Herein, we aimed to evaluate the systemic and splanchnic hemodynamic effects of β-blockers in decompensated vs. compensated cirrhosis and to investigate the influence of systemic hemodynamic changes on survival times in decompensated cirrhosis. METHODS: Patients with cirrhosis and high-risk esophageal varices, without previous bleeding, were consecutively included and grouped according to the presence or absence of decompensation (ascites with or without overt encephalopathy). Systemic and hepatic hemodynamic measurements were performed before starting β-blockers and again after 1 to 3 months of treatment (short-term). RESULTS: Four hundred and three patients were included (190 decompensated and 213 compensated). At baseline, decompensated patients had higher portal pressure than compensated patients and were more hyperdynamic, with higher cardiac output (CO) and lower arterial pressure. Under β-blockers, decompensated patients had lower portal pressure decrease (10 ± 18% vs. 15 ± 12%; p <0.05) and had greater reductions in heart rate (p <0.001) and CO (17 ± 15% vs. 10 ± 21%; p <0.01). Among patients with decompensated cirrhosis, those who died had a greater decrease in CO with β-blockers than survivors (21 ± 14% vs. 15 ± 16%; p <0.05) and CO under β-blockers independently predicted death by competing-risk regression analysis, with good diagnostic accuracy (C-index 0.74; 95% CI 0.66-0.83). Death risk was higher in decompensated patients with CO <5 L/min vs. CO ≥5 L/min (subdistribution hazard ratio 0.44; 95% CI 0.25-0.77; p = 0.004). CONCLUSIONS: In patients with high-risk varices treated to prevent first bleeding, the systemic hemodynamic response to β-blockers is greater and the portal pressure decrease is smaller in those with decompensated cirrhosis. The short-term effect of β-blockers on CO might adversely influence survival in decompensated cirrhosis. LAY SUMMARY: β-blockers are often used to reduce the risk of variceal bleeding in patients with cirrhosis. However, it is not known whether the effect of β-blockers on arterial pressure and/or cardiac function may offset the benefit of reducing portal pressure. Herein, we show that in patients with decompensated cirrhosis the potentially detrimental systemic effects of β-blockers are greater than in compensated patients, while the beneficial pressure lowering effects are reduced. The short-term effect of β-blockers on cardiac output may adversely influence survival in patients with decompensated cirrhosis.
引用
- Alvarado-Tapias E, Ardevol A, Garcia-Guix M, et al. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol. 2020. PMID: 32298768. doi:10.1016/j.jhep.2020.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。